Treating Pregnant and Lactating Patients with Dermatologic Conditions
MotherToBaby supports dermatologists in managing skin conditions during a patient’s reproductive years. We understand the challenges that you face when deciding on treatment courses when your patient is pregnant or breastfeeding. Whether tending to a patient with a pre-existing illness like psoriasis or atopic dermatitis, or a pregnancy dermatosis like PUPPP, our resources will help you weigh the risks and benefits to both your patient who is pregnant and their baby as you determine a treatment plan that maximizes disease management and minimizes maternal and fetal/infant risk.
We are also dedicated to furthering the information and understanding of medication safety in pregnancy through our observational MotherToBaby Pregnancy Studies. We are proud to lead more than half of all Food and Drug Administration (FDA)-mandated pregnancy registries conducted in the U.S., including studies on psoriasis and atopic dermatitis treatments. MotherToBaby Pregnancy Studies are rigorously designed cohort studies that aim to provide critically needed product safety information – and your patient referrals make all the difference. With your referral, you are helping us generate data that will lead to improved product safety information in pregnancy, thereby providing you and your patients with the evidence you need to make more informed treatment decisions.
Dermatologists are frequently faced with questions about the safety of commonly prescribed topical and systemic medications during pregnancy and lactation from [people] of childbearing age who are pregnant, considering pregnancy, or breastfeeding. Safety data, particularly regarding medications that are unique to dermatology, can be difficult to locate and are not consolidated in a single reference guide for clinicians.— Murase et al. J Am Acad Dermatol. 2014;70(3):401.e1-415.
Explore how we can help you and your pregnant and breastfeeding patients by providing no-cost exposure risk assessments, patient education materials, observational studies to monitor pregnancy outcomes, and more.
- Adbry™ (tralokinumab-ldrm)
- COVID-19 mRNA Vaccines
- Cimzia® (certolizumab pegol)
- Coronavirus (COVID-19)
- Dupixent® (dupilumab)
- Eczema (Moderate-to-Severe)/Atopic Dermatitis
- Ilumya™ (tildrakizumab-asmn)
- Otezla® (apremilast) (NO LONGER ENROLLING)
- Psoriatic Arthritis
- Tremfya® (guselkumab)
- Xeljanz® (tofacitinib citrate) (NO LONGER ENROLLING)
Related Fact Sheets
- Adalimumab (Humira®)
- Apremilast (Otezla®)
- Atopic Dermatitis | Eczema
- Azathioprine | 6-mercaptopurine
- Certolizumab Pegol (Cimzia®)
- Dupilumab (Dupixent®)
- Etanercept (Enbrel®)
- Infliximab (Remicade®)
- Isotretinoin (Accutane®)
- Mpox (Monkeypox)
- Paternal Exposures
- Prednisone | Prednisolone
- Psoriasis and Psoriatic Arthritis
- Staphylococcus aureus (Staph infection)
- Tildrakizumab (Ilumya®)
- Tofacitinib (Xeljanz®, Xeljanz XR®)
- Topical Acne Treatments
- Topical Corticosteroids
- Topical Tretinoin
- Tralokinumab (Adbry ®)
- Ustekinumab (Stelara®)
We provide no-cost, evidence-based info on exposures during pregnancy or breastfeeding by phone, text, email, and chat.
We offer free patient education materials and provider resources for our information service and pregnancy studies.
Download our LactRx app for on-the-go access to the Library of Medicine’s LactMed database for current information on dermatology medications as well as other drugs and vaccinations to which breastfeeding mothers may be exposed.
- Society for Maternal-Fetal Medicine
- Society for Birth Defects Research & Prevention
- Patient Education Genius
- The Mighty
Get answers to the most frequently asked questions about our information service and pregnancy studies.
Stay In Touch
Our e-Newsletter brings you the latest information, news, and resources from the experts at MotherToBaby.
Refer a Patient
Need to give your patient a personalized assessment on an exposure risk or connect them to our pregnancy studies?